

Lin BioScience, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
December 31, 2020 and 2019
(In Thousands of New Taiwan Dollars)

	December 31, 2020		December 31, 2019	
	Amount	%	Amount	%
ASSETS				
CURRENT ASSETS				
Cash and cash equivalents	\$ 1,092,252	90	\$ 117,145	47
Current tax assets	27	-	96	-
Other current assets	17,109	1	12,384	5
Total current assets	1,109,388	91	129,625	52
NON-CURRENT ASSETS				
Property, plant and equipment	2,464	-	3,629	1
Right-of-use assets	5,086	1	7,992	3
Other intangible assets	100,234	8	106,079	43
Prepayments for equipment	573	-	-	-
Refundable deposits	1,114	-	1,397	1
Total non-current assets	109,471	9	119,097	48
TOTAL	\$ 1,218,859	100	\$ 248,722	100
LIABILITIES AND EQUITY				
CURRENT LIABILITIES				
Financial liabilities at fair value through profit or loss - current	\$ 272,214	22	\$ 12	-
Other payables	29,680	3	36,786	15
Lease liabilities - current	2,913	-	2,833	1
Corporate bonds payable	-	-	59,948	24
Other current liabilities	1,822	-	1,234	1
Total current liabilities	306,629	25	100,813	41
NON-CURRENT LIABILITIES				
Lease liabilities - non-current	2,241	-	5,154	2
Total liabilities	308,870	25	105,967	43
EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT				
Share capital				
Share capital	685,000	57	595,000	239
Capital collected in advance	2,150	-	-	-
Total share capital	687,150	57	595,000	239
Capital surplus	952,748	78	125,430	50
Accumulated deficits	(726,925)	(60)	(575,081)	(231)
Other equity	(630)	-	(3,538)	(1)
Total equity attributable to owners of the Parent	912,343	75	141,811	57
NON-CONTROLLING INTERESTS				
	(2,354)	-	944	-
Total equity	909,989	75	142,755	57
TOTAL	\$ 1,218,859	100	\$ 248,722	100

Lin BioScience, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Years Ended December 31, 2020 and 2019
(In Thousands of New Taiwan Dollars, Except Loss Per Share)

	2020		2019	
	Amount	%	Amount	%
OPERATING REVENUE	\$ -	-	\$ -	-
OPERATING COSTS	-	-	-	-
GROSS PROFIT	-	-	-	-
OPERATING EXPENSES				
Marketing expenses	2,920	-	4,672	-
General and administrative expenses	49,065	-	40,203	-
Research and development expenses	145,009	-	193,346	-
Total operating expenses	196,994	-	238,221	-
LOSS FROM OPERATIONS	(196,994)	-	(238,221)	-
NON-OPERATING INCOME AND EXPENSES				
Interest income	502	-	341	-
Other income	-	-	21	-
Other gains and losses	21,956	-	(1,811)	-
Finance costs	(261)	-	(361)	-
Total non-operating income and expenses	22,197	-	(1,810)	-
LOSS BEFORE INCOME TAX	(174,797)	-	(240,031)	-
INCOME TAX BENEFIT	(22,953)	-	(4,775)	-
NET LOSS FOR THE YEAR	(151,844)	-	(235,256)	-
OTHER COMPREHENSIVE INCOME				
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translating the financial statements of foreign operations	\$ 2,892	-	(\$ 603)	-
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(\$ 148,952)	-	(\$ 235,859)	-
NET LOSS ATTRIBUTABLE TO:				
Owners of the Parent	(\$ 151,844)	-	(\$ 235,256)	-
Non-controlling interests	-	-	-	-
	(\$ 151,844)	-	(\$ 235,256)	-
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO:				
Owners of the Parent	(\$ 148,952)	-	(\$ 235,830)	-
Non-controlling interests	-	-	(29)	-
	(\$ 148,952)	-	(\$ 235,859)	-
LOSS PER SHARE				
Basic and diluted	(\$ 2.44)		(\$ 3.95)	